

What is the Galleri™ test?

Galleri is a multi-cancer early detection test that can detect more than 50 types of cancers¹ through a simple blood draw. The Galleri test is intended to be complementary to, and not a replacement of, U.S. guideline-recommended cancer screenings that a healthcare provider may recommend. Galleri can give patients the potential benefits of:

- » **Early cancer detection:** Detects many cancers that are not commonly screened for today, to allow for earlier treatment.²
- » **Testing with ease:** Can be incorporated into a routine healthcare visit.
- » **Actionable results:** If a cancer signal is found, the results can point to where in the body the cancer is coming from with high accuracy to help healthcare providers guide the next steps.

How the Galleri test works

All cells in your body release DNA into the bloodstream, but DNA from cancer cells is different from the DNA of healthy cells. The Galleri test uses the power of next-generation sequencing and machine-learning algorithms to look at the DNA in your blood to determine if any of it may have come from cancer cells. Using its proprietary methylation technology, Galleri can also help point to where in the body the cancer is coming from.

In a clinical study, Galleri showed the ability to detect more than 50 types of cancers – over 45 of which lack recommended screening today – with a low false positive rate of less than 1%. When a cancer signal is detected, the Galleri test also identified where the cancer signal originated in the body with high accuracy. This helps enable healthcare providers to determine next steps for diagnosis and care.

How to get the Galleri test

1. The Galleri test is available by prescription only. Patients should talk to their healthcare provider to determine if the test is right for them.
2. Patients can complete a blood draw at their healthcare provider's office or at one of GRAIL's partner laboratories, including at Quest laboratory locations.
3. Ordering physician receives the test results within 10 business days after the specimen is received and, if necessary, determines next steps for their patient.

Learn more at www.galleri.com.

Media contact: pr@grail.com

Important Safety Information: The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests. Results should be interpreted by a healthcare provider. A "Cancer Signal Not Detected" result does not rule out cancer. A "Cancer Signal Detected" result requires confirmatory diagnostic evaluation (e.g. imaging), and if cancer is not confirmed, it may not be present, may not be detectable by diagnostic follow-up testing or may be located in a different part of the body. False-positive and false-negative test results do occur. Rx only.

Laboratory / test information: The GRAIL laboratory is CLIA-certified and CAP-accredited. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by FDA. The GRAIL laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is for clinical purposes.

1. Amin MB, et al. (Eds). American Joint Committee of Cancer (AJCC) Cancer Staging Manual (8th edition)
2. The Galleri test does not detect all cancers nor does it measure your genetic risk of developing cancer in the future. It should be used in addition to routine screening tests your healthcare provider recommends.
3. Klein E, et al. Oral presentation at: American Association for Cancer Research 2021 Annual Meeting (Virtual); April 10-15, 2021. Abstract LB013.

Fast Facts

50+
types of cancers detected¹

**Less than
1% false positive rate**
(99.5% specificity)

44%
positive predictive value³

**140+ clinical
study sites**
that contributed to the
development of Galleri

Developed as part of
**one of the largest
clinical study
programs**
in genomic medicine

Published papers
in multiple peer-reviewed
journals and presented data at
dozens of medical conferences
from 2017 through today

